Skip to main content
Equibles
PTCT logo

PTCT

Ptc Therapeutics, Inc.
$84.85 -4.70 (-5.25%) At close · Jul 10
Market Cap
$7.04B
Shares
82,949,338

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$84.85 Open$89.71 Day$83.83–89.71 52W$43.18–90.87 Avg vol 30d2.1M Short int17.3M · 20.9% float · 5.4d Short vol66% Last earningsMay 7, 2026 DataJan 2020–Jul 2026 Filing10-Q · May 7
Up next
Next earnings call
Aug 1, 2026 Est · unconfirmed · in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 7, 2026
AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Equibles Rating blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Strong Buy Momentum Very Strong Sentiment Bearish Fundamentals Excellent Quant / Vol High
      Market backdrop VIX 15 · calm Equity put/call 0.55
      Technical
      price trend
      Strong Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +18%
      above
      Price vs 50-day avg +13%
      above
      RSI (14) 59
      neutral
      MACD trend Positive
      52-week position 87%
      near high
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +16%
      trailing
      6-month return +12%
      trailing
      YTD return +12%
      this year
      Relative strength +3%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bearish
      Trend (MA cross) No cross
      50d $75 › 200d $72 — 50d above 200d
      Institutional flow Distributing
      17 of 351 funds reported for Jun 30 · net -39.9K sh shares · +5 new
      Insider flow Distributing
      Net -$3.2M over 90 days · 100% sells
      Short interest Rising
      20.87% of float · ▲ +46.9% MoM · 5.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      351 holders — near 3-yr high, broad support
      Squeeze score 79
      high risk · 0–100
      Fundamentals
      Excellent
      Revenue growth +36%
      Y/Y
      EPS growth +264%
      Y/Y
      Free cash flow $702.3M
      Balance sheet $412.6M
      net cash
      Quant / Vol
      risk profile
      High
      Volatility 44%
      annualized · 1-yr
      Max drawdown −27%
      past year
      ATR 4.3%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record
      Latest guidance · from the Earnings Call filed Mar 31, 2026
      Product revenue · 2026 full-year Initiated $750M – $850M
      prior FY $1.73B midpoint −53.8% Y/Y
      Total revenue · 2026 full-year Raised $1.08B – $1.18B
      prior FY $1.73B midpoint −34.7% Y/Y

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Strong Buy
      0 · 3 · 4
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +18% Bullish
      Price vs 50-day avg
      +13% Bullish
      RSI (14)
      59 Neutral
      MACD trend
      Positive Bullish
      52-week position
      87% Bullish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bearish · 3 of 6
      Trend (MA cross) No cross
      50d $75 › 200d $72 — 50d above 200d
      Institutional flow Distributing
      17 of 351 funds reported for Jun 30 · net -39.9K sh shares · +5 new
      Insider flow Distributing
      Net -$3.2M over 90 days · 100% sells
      Short interest Rising
      20.87% of float · ▲ +46.9% MoM · 5.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      351 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      52-wk low $43 Now $85 · 87% 52-wk high $91
      vs 200-day avg +18% vs 50-day avg +13%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      Patients on commercial therapy worldwide 1,244 Q1 2026 —
      Shares issued and outstanding 82,882,024 March 31, 2026 —
      commercial patients globally 1,244 Q1 FY2026 call —
      DMD franchise revenue $81M Q1 FY2026 call —
      Emflasa quarterly revenue $22M Q1 FY2026 call —
      Forvey Dee global revenue $585M Q1 FY2026 call —
      global prescriptions 2,200 Q1 FY2026 call —
      royalty revenue $47M Q1 FY2026 call —
      Suffiance Global revenue $125M Q1 FY2026 call —
      Suffiance international revenue $13M Q1 FY2026 call —
      Suffiance U.S. revenue $112M Q1 FY2026 call —
      translarna net product revenue $59M Q1 FY2026 call —
      U.S. patient start forms 1,500 Q1 FY2026 call —
      Patient start forms received in the US 1,134 as of December 31, 2025 —
      Sephience ex-US Q4 2025 revenue $11M Q4 2025 —
      Sephience Q4 2025 revenue $92M Q4 2025 —
      Sephience total net revenue since launch $111M Full Year 2025 —
      Sephience US Q4 2025 revenue $81M Q4 2025 —
      Total patients on commercial therapy worldwide 946 as of December 31, 2025 —
      Sephience Q4 2025 ex-US net revenue $10.9M Q4 2025 —
      Sephience Q4 2025 net revenue $92.5M Q4 2025 —
      Sephience Q4 2025 US net revenue $81.6M Q4 2025 —

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      PTCT
      Ptc Therapeutics, Inc.
      this stock
      		$7.04B +11.7% +34.2% — 20.9%
      ONC
      BeOne Medicines Ltd.
      		 $431.70B -1.7% +22179.2% 878.5 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $123.19B +7.1% +46.2% 28.8 1.9%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $69.67B -13.8% +20.8% 16.2 3.3%
      ARGX
      Argenx SE
      		 $54.85B +4.4% — — 2.3%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      356
      % held
      110.4%
      Reported
      17 of 351
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      416
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      17.3M
      Days to cover
      5.4d
      Change
      +5.5M sh
      View
      Short Volume
      Short vol %
      66%
      As of
      Jul 10, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      7
      Value
      $523
      As of
      Jun 12, 2026
      View
      Off-Exchange
      Off-exchange %
      48.7%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$3.2M
      Buyers / Sellers
      0 / 3
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $1.7B
      Net income (FY)
      $682.6M
      EPS diluted
      $7.78
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jun 18, 2026
      This year
      13
      View
      Proposed Sales
      Value
      $222.4K
      Shares
      2.5K
      Filed
      Jul 9, 2026
      View
      Exempt Offerings
      Offering
      $35.9M
      Filed
      May 8, 2023
      View
      Earnings & Events
      Earnings Calls
      Last call
      May 7, 2026
      View
      Investor Relations
      Latest news
      PTC Therapeutics Reports Induceme…
      Published
      Jun 17, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      PTCT +1.9% +15.7% +12.2% +4.0% +11.7%
      SPY +1.4% +4.1% +9.1% +1.1% +10.7%
      vs SPY +0.5% +11.6% +3.1% +2.9% +1.0%
      Key facts CIK 1070081 CUSIP 69366J200 13F (30d) 19 filings 18 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)